Scholar Rock Holding Corporation
Financials
Valuation Metrics
Scholar Rock Holding Corporation's Market Cap is $5.15B. At end of 2025 it was $5.05B. Ranked #1303 of 3,118 in US market (top 42%), #434 of 1,474 on NASDAQ (top 29%), #74 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.15B | US#1,303/3,118 Sec#74/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-409M | US—/3,118 Sec—/265 |
| Total Assets | $524M | US#2,738/3,118 Sec#157/265 |
| Net Assets | $254M | US#2,578/3,118 Sec#166/265 |
| Employees | 289 | US#2,415/3,118 Sec#113/265 |
| Value | ||
| P/B | 20.29x | US#2,792/3,118 Sec#219/265 |
| FCF Yield | -5.76% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -161.00% | US#2,823/3,118 Sec#215/265 |
| ROA | -78.04% | US#3,035/3,118 Sec#246/265 |
| Financial Health | ||
| Debt Ratio | 106.29% | US#1,146/3,118 Sec#166/265 |
| Total Debt | $204M | US#2,231/3,118 Sec#95/265 |
| FCF | $-296M | US#2,842/3,118 Sec#231/265 |
| Cash | $437M | US#1,154/3,118 Sec#63/265 |
| Current Ratio | 7.02x | US#349/3,118 Sec#108/265 |
| Performance | ||
| 1Y Return | 45.07% | US#502/3,118 Sec#74/265 |
| 1M Return | -8.20% | US#2,420/3,118 Sec#179/265 |
| From 52W High | -30.42% | US#1,898/3,118 Sec#115/265 |
| 1Y MDD | -34.04% | US#1,581/3,118 Sec#84/265 |
| Trading | ||
| Volume | 744,802 shares | US#2,055/3,118 Sec#202/265 |
| Trading Value | $32M | US#1,830/3,118 Sec#136/265 |
| Per Share | ||
| EPS | $-3.41 | US—/3,118 Sec—/265 |
| BPS | $2.12 | US#2,560/3,118 Sec#176/265 |
Company Info
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.